Posted in | News | Chemistry

Researchers Synthesize Molecules that Exhibit Unprecedented Isotopic Atropisomerism

Isotopes are atoms that have the same number of protons but a different number of neutrons. Compounds consisting of stable isotopes have been used as probes in chemistry or molecular biology to study the structure of different molecules.

Deuterium (D), an isotope of hydrogen, is a common molecular label used by scientists to understand reaction pathways and drug activity and to identify organ toxicities. Organic compounds "labeled" or tagged with deuterium can also act as excellent solvents for analytical techniques like nuclear magnetic resonance (NMR) spectroscopy.

Deuterated chiral organic compounds-;molecules that are non-superimposable mirror images of each other-;act as perfect probe molecules for mechanistic studies of various biochemical and synthetic reactions. Over the years, scientists have developed many reactions for the synthesis of optically active chiral deuterated compounds. However, most of them are centrally chiral compounds bearing a chiral carbon, while the synthesis of atropisomeric chiral deuterated compounds has not been reported yet because of "racemization" and difficulty of detecting the atropisomerism based on H/D discrimination.

To overcome this issue, a team of researchers from Shibaura Institute of Technology (SIT), Japan, led by Professor Osamu Kitagawa synthesized 3-(2-deuteriophenyl)-2-(1-phenylpropan-2-yl)quinazoline-4-thiones. The molecules showed unprecedented isotopic atropisomerism— a form of chirality that arises due to the difference in a bond rotation that arises from steric hindrance. The atropisomerism in the prepared quinazoline-4-one derivatives was due to rotational restriction around an N-Ar(deuterio-phenyl ) bond. As Prof. Kitagawa explains, “We were trying to understand the chemistry of N-C axially chiral compounds which is when we discovered atropisomers based on ortho-H/F discrimination. These were rare compounds where the smallest hydrogen atom and the second smallest fluorine atom were at the ortho position. This gave us an idea about creating isomers based on ortho-H/D discrimination.” The findings of their study are published in Organic Letters.

Optically active 3-(2-deuteriophenyl)-2-(1-phenylpropan-2-yl)quinazoline-4-thione was prepared via highly diastereoselective α-benzylation of a precursor [optically pure 3-(2-bromophenyl)-2-ehyl quinazolin-4-one] followed by thionation with Lawesson's reagent and then "deuteration" using sodium boro-deutiride. This synthesis was achieved by Kazuya Saito and Shota Miwa, who are graduate students in Kitagawa's lab.

The team (mainly Dr. Elsa Caytan at University of Rennes who is co-worker) then analyzed the samples using 1H- and 2H-NMR, which clearly indicated that the quinazoline-4-thiones existed as a 1:1 mixture of diastereomers based on a chiral carbon atom and atropisomerism due to the rotational restriction around an N-aryl bond. Density functional theory (DFT) calculations, which were performed by Dr. Yuuki Fujimoto (co-worker), also strongly supports the formation of diastereomers. 

This study is the first to detect a class 2 isotopic atropisomer based on the difference in ortho-H/D. The molecules synthesized during this research could also be used for pharmaceutical purposes. "The N aryl quinazolinones and the thione analogs prepared during our study are multifunctional. Not only can they be used as probe molecules but are also of great interest from a medicinal chemistry point of view. Quinazoline-4-thiones are known to have high biological activity. They can be used to develop therapeutic agents with show antibacterial, anti-inflammatory, and anti-cancer properties," concludes Prof. Kitagawa.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.